Global Beta lactam and Beta lactamase Inhibitors Market Research Report 2023(Status and Outlook)

Global Beta lactam and Beta lactamase Inhibitors Market Research Report 2023(Status and Outlook)



Report Overview

β-Lactams are the most widely used class of antibiotics. Since the discovery of benzylpenicillin in the 1920s, thousands of new penicillin derivatives and related β-lactam classes of cephalosporins, cephamycins, monobactams, and carbapenems have been discovered. Each new class of b-lactam has been developed either to increase the spectrum of activity to include additional bacterial species or to address specific resistance mechanisms that have arisen in the targeted bacterial population. Resistance to β-lactams is primarily because of bacterially produced β-lactamase enzymes that hydrolyze the β-lactam ring, thereby inactivating the drug. The newest effort to circumvent resistance is the development of novel broad-spectrum β-lactamase inhibitors that work against many problematic β-lactamases, including cephalosporinases and serine-based carbapenemases, which severely limit therapeutic options.

In the global market, the core manufacturers of Beta-lactam and Beta-lactamase Inhibitors include Pfizer and Novartis (Sandoz) etc, and the top 2 manufacturers account for about 10% of the market share. The market include Asia Pacific, Europe and North America, with a share of 33%, 32% and 28%. cephalosporins accounted for 28% and penicillins accounted for 17%. The product is mainly used in intravenous and oral, with a share of 65% and 35%.

The Global Beta lactam and Beta lactamase Inhibitors Market Size was estimated at USD 23720.00 million in 2022 and is projected to reach USD 27060.39 million by 2029, exhibiting a CAGR of 1.90% during the forecast period.

Bosson Research’s latest report provides a deep insight into the global Beta lactam and Beta lactamase Inhibitors market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Beta lactam and Beta lactamase Inhibitors Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Beta lactam and Beta lactamase Inhibitors market in any manner.

Global Beta lactam and Beta lactamase Inhibitors Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Pfizer

Novartis (Sandoz)

TEVA

Merck

AbbVie (Allergan)

Sumitomo Dainippon

Hikma

Aurobindo Pharma

Wockhardt

Lupin Limited

Fresenius Kabi

B. Braun

USantibiotics

Qilu Pharmaceutical

ACS Dobfar

Nichi-Iko (Sagent)

Antibiotice

Market Segmentation (by Type)

Penicillins

Cephalosporins

Carbapenems

Monobactams

Combinations

Market Segmentation (by Application)

Hospital

Clinic

Health Center

Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Beta lactam and Beta lactamase Inhibitors Market

Overview of the regional outlook of the Beta lactam and Beta lactamase Inhibitors Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Beta lactam and Beta lactamase Inhibitors
1.2 Key Market Segments
1.2.1 Beta lactam and Beta lactamase Inhibitors Segment by Type
1.2.2 Beta lactam and Beta lactamase Inhibitors Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Beta lactam and Beta lactamase Inhibitors Market Overview
2.1 Global Market Overview
2.1.1 Global Beta lactam and Beta lactamase Inhibitors Market Size (M USD) Estimates and Forecasts (2018-2029)
2.1.2 Global Beta lactam and Beta lactamase Inhibitors Sales Estimates and Forecasts (2018-2029)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Beta lactam and Beta lactamase Inhibitors Market Competitive Landscape
3.1 Global Beta lactam and Beta lactamase Inhibitors Sales by Manufacturers (2018-2023)
3.2 Global Beta lactam and Beta lactamase Inhibitors Revenue Market Share by Manufacturers (2018-2023)
3.3 Beta lactam and Beta lactamase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Beta lactam and Beta lactamase Inhibitors Average Price by Manufacturers (2018-2023)
3.5 Manufacturers Beta lactam and Beta lactamase Inhibitors Sales Sites, Area Served, Product Type
3.6 Beta lactam and Beta lactamase Inhibitors Market Competitive Situation and Trends
3.6.1 Beta lactam and Beta lactamase Inhibitors Market Concentration Rate
3.6.2 Global 5 and 10 Largest Beta lactam and Beta lactamase Inhibitors Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Beta lactam and Beta lactamase Inhibitors Industry Chain Analysis
4.1 Beta lactam and Beta lactamase Inhibitors Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Beta lactam and Beta lactamase Inhibitors Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Beta lactam and Beta lactamase Inhibitors Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Beta lactam and Beta lactamase Inhibitors Sales Market Share by Type (2018-2023)
6.3 Global Beta lactam and Beta lactamase Inhibitors Market Size Market Share by Type (2018-2023)
6.4 Global Beta lactam and Beta lactamase Inhibitors Price by Type (2018-2023)
7 Beta lactam and Beta lactamase Inhibitors Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Beta lactam and Beta lactamase Inhibitors Market Sales by Application (2018-2023)
7.3 Global Beta lactam and Beta lactamase Inhibitors Market Size (M USD) by Application (2018-2023)
7.4 Global Beta lactam and Beta lactamase Inhibitors Sales Growth Rate by Application (2018-2023)
8 Beta lactam and Beta lactamase Inhibitors Market Segmentation by Region
8.1 Global Beta lactam and Beta lactamase Inhibitors Sales by Region
8.1.1 Global Beta lactam and Beta lactamase Inhibitors Sales by Region
8.1.2 Global Beta lactam and Beta lactamase Inhibitors Sales Market Share by Region
8.2 North America
8.2.1 North America Beta lactam and Beta lactamase Inhibitors Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Beta lactam and Beta lactamase Inhibitors Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Beta lactam and Beta lactamase Inhibitors Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Beta lactam and Beta lactamase Inhibitors Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Beta lactam and Beta lactamase Inhibitors Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Pfizer
9.1.1 Pfizer Beta lactam and Beta lactamase Inhibitors Basic Information
9.1.2 Pfizer Beta lactam and Beta lactamase Inhibitors Product Overview
9.1.3 Pfizer Beta lactam and Beta lactamase Inhibitors Product Market Performance
9.1.4 Pfizer Business Overview
9.1.5 Pfizer Beta lactam and Beta lactamase Inhibitors SWOT Analysis
9.1.6 Pfizer Recent Developments
9.2 Novartis (Sandoz)
9.2.1 Novartis (Sandoz) Beta lactam and Beta lactamase Inhibitors Basic Information
9.2.2 Novartis (Sandoz) Beta lactam and Beta lactamase Inhibitors Product Overview
9.2.3 Novartis (Sandoz) Beta lactam and Beta lactamase Inhibitors Product Market Performance
9.2.4 Novartis (Sandoz) Business Overview
9.2.5 Novartis (Sandoz) Beta lactam and Beta lactamase Inhibitors SWOT Analysis
9.2.6 Novartis (Sandoz) Recent Developments
9.3 TEVA
9.3.1 TEVA Beta lactam and Beta lactamase Inhibitors Basic Information
9.3.2 TEVA Beta lactam and Beta lactamase Inhibitors Product Overview
9.3.3 TEVA Beta lactam and Beta lactamase Inhibitors Product Market Performance
9.3.4 TEVA Business Overview
9.3.5 TEVA Beta lactam and Beta lactamase Inhibitors SWOT Analysis
9.3.6 TEVA Recent Developments
9.4 Merck
9.4.1 Merck Beta lactam and Beta lactamase Inhibitors Basic Information
9.4.2 Merck Beta lactam and Beta lactamase Inhibitors Product Overview
9.4.3 Merck Beta lactam and Beta lactamase Inhibitors Product Market Performance
9.4.4 Merck Business Overview
9.4.5 Merck Beta lactam and Beta lactamase Inhibitors SWOT Analysis
9.4.6 Merck Recent Developments
9.5 AbbVie (Allergan)
9.5.1 AbbVie (Allergan) Beta lactam and Beta lactamase Inhibitors Basic Information
9.5.2 AbbVie (Allergan) Beta lactam and Beta lactamase Inhibitors Product Overview
9.5.3 AbbVie (Allergan) Beta lactam and Beta lactamase Inhibitors Product Market Performance
9.5.4 AbbVie (Allergan) Business Overview
9.5.5 AbbVie (Allergan) Beta lactam and Beta lactamase Inhibitors SWOT Analysis
9.5.6 AbbVie (Allergan) Recent Developments
9.6 Sumitomo Dainippon
9.6.1 Sumitomo Dainippon Beta lactam and Beta lactamase Inhibitors Basic Information
9.6.2 Sumitomo Dainippon Beta lactam and Beta lactamase Inhibitors Product Overview
9.6.3 Sumitomo Dainippon Beta lactam and Beta lactamase Inhibitors Product Market Performance
9.6.4 Sumitomo Dainippon Business Overview
9.6.5 Sumitomo Dainippon Recent Developments
9.7 Hikma
9.7.1 Hikma Beta lactam and Beta lactamase Inhibitors Basic Information
9.7.2 Hikma Beta lactam and Beta lactamase Inhibitors Product Overview
9.7.3 Hikma Beta lactam and Beta lactamase Inhibitors Product Market Performance
9.7.4 Hikma Business Overview
9.7.5 Hikma Recent Developments
9.8 Aurobindo Pharma
9.8.1 Aurobindo Pharma Beta lactam and Beta lactamase Inhibitors Basic Information
9.8.2 Aurobindo Pharma Beta lactam and Beta lactamase Inhibitors Product Overview
9.8.3 Aurobindo Pharma Beta lactam and Beta lactamase Inhibitors Product Market Performance
9.8.4 Aurobindo Pharma Business Overview
9.8.5 Aurobindo Pharma Recent Developments
9.9 Wockhardt
9.9.1 Wockhardt Beta lactam and Beta lactamase Inhibitors Basic Information
9.9.2 Wockhardt Beta lactam and Beta lactamase Inhibitors Product Overview
9.9.3 Wockhardt Beta lactam and Beta lactamase Inhibitors Product Market Performance
9.9.4 Wockhardt Business Overview
9.9.5 Wockhardt Recent Developments
9.10 Lupin Limited
9.10.1 Lupin Limited Beta lactam and Beta lactamase Inhibitors Basic Information
9.10.2 Lupin Limited Beta lactam and Beta lactamase Inhibitors Product Overview
9.10.3 Lupin Limited Beta lactam and Beta lactamase Inhibitors Product Market Performance
9.10.4 Lupin Limited Business Overview
9.10.5 Lupin Limited Recent Developments
9.11 Fresenius Kabi
9.11.1 Fresenius Kabi Beta lactam and Beta lactamase Inhibitors Basic Information
9.11.2 Fresenius Kabi Beta lactam and Beta lactamase Inhibitors Product Overview
9.11.3 Fresenius Kabi Beta lactam and Beta lactamase Inhibitors Product Market Performance
9.11.4 Fresenius Kabi Business Overview
9.11.5 Fresenius Kabi Recent Developments
9.12 B. Braun
9.12.1 B. Braun Beta lactam and Beta lactamase Inhibitors Basic Information
9.12.2 B. Braun Beta lactam and Beta lactamase Inhibitors Product Overview
9.12.3 B. Braun Beta lactam and Beta lactamase Inhibitors Product Market Performance
9.12.4 B. Braun Business Overview
9.12.5 B. Braun Recent Developments
9.13 USantibiotics
9.13.1 USantibiotics Beta lactam and Beta lactamase Inhibitors Basic Information
9.13.2 USantibiotics Beta lactam and Beta lactamase Inhibitors Product Overview
9.13.3 USantibiotics Beta lactam and Beta lactamase Inhibitors Product Market Performance
9.13.4 USantibiotics Business Overview
9.13.5 USantibiotics Recent Developments
9.14 Qilu Pharmaceutical
9.14.1 Qilu Pharmaceutical Beta lactam and Beta lactamase Inhibitors Basic Information
9.14.2 Qilu Pharmaceutical Beta lactam and Beta lactamase Inhibitors Product Overview
9.14.3 Qilu Pharmaceutical Beta lactam and Beta lactamase Inhibitors Product Market Performance
9.14.4 Qilu Pharmaceutical Business Overview
9.14.5 Qilu Pharmaceutical Recent Developments
9.15 ACS Dobfar
9.15.1 ACS Dobfar Beta lactam and Beta lactamase Inhibitors Basic Information
9.15.2 ACS Dobfar Beta lactam and Beta lactamase Inhibitors Product Overview
9.15.3 ACS Dobfar Beta lactam and Beta lactamase Inhibitors Product Market Performance
9.15.4 ACS Dobfar Business Overview
9.15.5 ACS Dobfar Recent Developments
9.16 Nichi-Iko (Sagent)
9.16.1 Nichi-Iko (Sagent) Beta lactam and Beta lactamase Inhibitors Basic Information
9.16.2 Nichi-Iko (Sagent) Beta lactam and Beta lactamase Inhibitors Product Overview
9.16.3 Nichi-Iko (Sagent) Beta lactam and Beta lactamase Inhibitors Product Market Performance
9.16.4 Nichi-Iko (Sagent) Business Overview
9.16.5 Nichi-Iko (Sagent) Recent Developments
9.17 Antibiotice
9.17.1 Antibiotice Beta lactam and Beta lactamase Inhibitors Basic Information
9.17.2 Antibiotice Beta lactam and Beta lactamase Inhibitors Product Overview
9.17.3 Antibiotice Beta lactam and Beta lactamase Inhibitors Product Market Performance
9.17.4 Antibiotice Business Overview
9.17.5 Antibiotice Recent Developments
10 Beta lactam and Beta lactamase Inhibitors Market Forecast by Region
10.1 Global Beta lactam and Beta lactamase Inhibitors Market Size Forecast
10.2 Global Beta lactam and Beta lactamase Inhibitors Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Beta lactam and Beta lactamase Inhibitors Market Size Forecast by Country
10.2.3 Asia Pacific Beta lactam and Beta lactamase Inhibitors Market Size Forecast by Region
10.2.4 South America Beta lactam and Beta lactamase Inhibitors Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Beta lactam and Beta lactamase Inhibitors by Country
11 Forecast Market by Type and by Application (2024-2029)
11.1 Global Beta lactam and Beta lactamase Inhibitors Market Forecast by Type (2024-2029)
11.1.1 Global Forecasted Sales of Beta lactam and Beta lactamase Inhibitors by Type (2024-2029)
11.1.2 Global Beta lactam and Beta lactamase Inhibitors Market Size Forecast by Type (2024-2029)
11.1.3 Global Forecasted Price of Beta lactam and Beta lactamase Inhibitors by Type (2024-2029)
11.2 Global Beta lactam and Beta lactamase Inhibitors Market Forecast by Application (2024-2029)
11.2.1 Global Beta lactam and Beta lactamase Inhibitors Sales (K MT) Forecast by Application
11.2.2 Global Beta lactam and Beta lactamase Inhibitors Market Size (M USD) Forecast by Application (2024-2029)
12 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings